Biosion, Inc. Insider Files SEC Form 3 – Quantisnow
Biosion, Inc. recently filed a Form 3 with the SEC, disclosing its beneficial ownership of securities in Aclaris Therapeutics, Inc. Here’s what you need to know about this insider transaction.
On November 18, 2024, Biosion, Inc. and Aclaris Therapeutics, Inc. entered into a Common Stock Purchase Warrant. This warrant allows Biosion, or its designee, to exercise the warrant for up to 11,281,985 shares of Aclaris Common Stock. The exercise period began on November 18, 2024, and will continue until the warrant is fully exercised.
The CEO of Biosion, Inc., Mingjiu Chen, signed the Form 3 on November 25, 2024, confirming the details of the transaction.
This transaction adds a significant number of shares of Aclaris Common Stock to Biosion’s portfolio. It’s a strategic move that enhances Aclaris’ pipeline by bringing in a complementary biologics portfolio.
Furthermore, Biosion is expanding its leadership team as part of this transaction. By adding seasoned biotech executives, the company is poised for future growth and success.
For more information on this insider transaction, you can access the full Form 3 filing on the SEC’s website. Stay tuned for further updates on Biosion, Inc. and Aclaris Therapeutics, Inc. by signing up for real-time alerts.
